Treatment Persistence and Safety of Apremilast in Psoriasis: Experience With 30 Patients in Routine Clinical Practice

被引：4
|
作者：
Sahuquillo-Torralba, A. [1 ]
de Unamuno Bustos, B. [1 ]
Rodriguez Serna, M. [1 ]
Monte Boquet, E. [2 ]
Botella Estrada, R. [1 ,3 ]
机构：
[1] Hosp Univ & Politecn La Fe, Serv Dermatol, Valencia, Spain
[2] Hosp Univ & Politecn La Fe, Serv Farm Hosp, Valencia, Spain
[3] Univ Valencia, Fac Med, Valencia, Spain
来源：
ACTAS DERMO-SIFILIOGRAFICAS | 2020年 / 111卷 / 05期
关键词：
Apremilast; Clinical practice; Specific locations; Adverse effects; ORAL PHOSPHODIESTERASE-4 INHIBITOR; SEVERE PLAQUE PSORIASIS; PHASE-III; EFFICACY; MODERATE; TRIALS;
D O I：
10.1016/j.ad.2018.10.031
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Apremilast is a phosphodiesterase-4 inhibitor taken orally. Little information about its use in routine clinical practice is available. We aimed to assess treatment safety and persistence rates in patients on apremilast for different forms of plaque psoriasis. This observational retrospective study included 30 patients with psoriasis who were treated with apremilast between January 2016 and December 2017 in our hospital. Twelve patients had palmar-plantar psoriasis, 8 had plaque psoriasis mainly on the scalp, and 10 had plaque psoriasis in other locations. The probable period of treatment persistence in patients in the 50th percentile was 18.5 months according to survival analysis of the series overall. Our experience suggests that apremilast is effective and safe for treating palmar-plantar psoriasis and plaques at other locations but not for treating scalp psoriasis. Adverse effects that compromise treatment occur in nearly two-thirds of the patients. (C) 2020 Published by Elsevier Espana, S.L.U. on behalf of AEDV.
引用
收藏
页码：415 / 418
页数：4
相关论文
共 50 条
  • [1] Effectiveness and safety of apremilast in biologic-naive patients with moderate psoriasis treated in routine clinical practice in Greece: the APRAISAL study
    Ioannides, D.
    Antonakopoulos, N.
    Georgiou, S.
    Chasapi, V
    Katsantonis, I
    Drosos, A.
    Rigopoulos, D.
    Antoniou, C.
    Anastasiadis, G.
    Bassukas, I
    Ioannidou, D.
    Protopapa, A.
    Neofotistou, O.
    Krasagakis, K.
    Aronis, P.
    Papageorgiou, M.
    Lazaridou, E.
    Patsatsi, A.
    Lefaki, I
    Roussaki-Schulze, A., V
    Satra, F.
    Anagnostopoulos, Z.
    Papakonstantis, M.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (09) : 1838 - 1848
  • [2] Safety evaluation of apremilast for the treatment of psoriasis
    Dattola, A.
    Del Duca, E.
    Saraceno, R.
    Gramiccia, T.
    Bianchi, L.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2017, 16 (03) : 381 - 385
  • [3] Safety of Apremilast in Patients with Psoriasis and Psoriatic Arthritis: Findings from the UK Clinical Practice Research Datalink
    Persson, Rebecca
    Cordey, Myriam
    Paris, Maria
    Jick, Susan
    [J]. DRUG SAFETY, 2022, 45 (11) : 1403 - 1411
  • [4] Safety of Apremilast in Patients with Psoriasis and Psoriatic Arthritis: Findings from the UK Clinical Practice Research Datalink
    Rebecca Persson
    Myriam Cordey
    Maria Paris
    Susan Jick
    [J]. Drug Safety, 2022, 45 : 1403 - 1411
  • [5] TREATMENT PERSISTENCE IN PSORIASIS PATIENTS INITIATED ON APREMILAST, ORAL SYSTEMICS, OR BIOLOGIC THERAPIES
    Feldman, S. R.
    Kaura, S.
    Li, S.
    Tencer, T.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A805 - A805
  • [6] An update on the safety of apremilast for the treatment of plaque psoriasis
    Shavit, Eran
    Shear, Neil H.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2020, 19 (04) : 403 - 408
  • [7] Real world experience on the effectiveness and safety of apremilast in patients with plaque psoriasis in India
    Dhoot, Dhiraj
    Deshmukh, Guarav
    Mahajan, Harshal
    Barkate, Hanmant
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB263 - AB263
  • [8] Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of palmoplantar psoriasis. Our experience in real clinical practice
    Aceituno-Madera, Pedro
    Salazar-Nievas, Maria
    Moreno-Suarez, Fatima
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB46 - AB46
  • [9] EFFICACY AND SURVIVAL OF APREMILAST IN PATIENTS WITH PSORIATIC ARTHRITIS AND PSORIASIS IN REAL CLINICAL PRACTICE
    Anon Onate, I.
    Perez Galan, M. J.
    Romero, A.
    Aceituno, P.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1657 - 1658
  • [10] TREATMENT PERSISTENCE OF BIOLOGICAL THERAPY IN RHEUMATOID ARTHRITIS (RA) PATIENTS IN ROUTINE CLINICAL PRACTICE
    Sousa, S. I.
    Cordeiro, I.
    Ferreira, D.
    Andreozzi, V.
    Felix, J.
    Jorge, A.
    da Silva, J. Canas
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1057 - 1057
12345